Indegene has announced the acquisition of BioPharm Communications, a Pennsylvania-based marketing agency that specializes in healthcare and pharmaceutical advertising. The deal, executed through ILSL Inc, a wholly owned subsidiary of Indegene Limited, brings enhanced AdTech and omnichannel media capabilities into Indegene’s commercialization offerings.
This move enables Indegene to offer pharmaceutical clients more precise, scalable, and performance-driven digital marketing solutions, combining AI technologies with deep industry knowledge. The acquisition also positions Indegene as a leading force in data-led, AI-driven engagement strategies for life sciences companies.
Founded in 2005, BioPharm serves 17 of the world’s top 25 pharmaceutical companies and brings extensive experience in end-to-end media strategy — including planning, buying, execution, and analytics. Their approach integrates automation, data science, and targeted outreach to deliver measurable marketing outcomes tailored to complex therapeutic areas.
Manish Gupta, Chairman and CEO of Indegene, commented “BioPharm has built a strong foundation through its technology, therapeutic insights, and longstanding client relationships. Bringing them into the Indegene fold strengthens our position as a key commercialization partner for pharma companies looking to modernize their go-to-market strategies. We are excited to welcome Steve and his team as we jointly accelerate the evolution of pharma marketing.”
Steve Carickhoff, President of BioPharm, added “Joining Indegene is a natural step forward for BioPharm. Their commitment to innovation, combined with robust data platforms, domain depth, and a truly global footprint, allows us to bring even more value to our clients. We’re aligned in vision and purpose and are eager to collaborate on advancing AI-powered marketing models that are both impactful and patient-centric.”
As pharmaceutical companies adapt to a shifting landscape — where physicians prefer minimal interaction, regulatory demands are rising, and product pipelines are diversifying — the need for more efficient, digital-first marketing strategies has grown. Traditional agency models are proving insufficient, pushing life sciences firms to seek specialized, tech-enabled partners like Indegene.
This acquisition is especially timely, with companies seeking to manage both mature brands and launch new therapies in highly competitive and digitally complex environments. Together, Indegene and BioPharm offer a powerful combination of data infrastructure, campaign expertise, and AI tools to drive improved marketing efficiency and greater return on investment.
Indegene Limited is a global provider of technology-enabled services for the life sciences industry. Working across the commercialization lifecycle — from clinical through medical to marketing — Indegene supports the world’s leading pharmaceutical companies in bringing therapies to market faster and more effectively. With over 25 years of experience, Indegene blends domain knowledge with purpose-built technology and operational strength to deliver value across every stage of the product journey.
Founded in 2005 and based in New Hope, Pennsylvania, BioPharm Communications specializes in healthcare marketing strategies designed for pharmaceutical and biotech organizations. The agency offers targeted engagement through a proprietary database of over three million healthcare professionals. BioPharm’s services span data-driven content development, addressable media, and omnichannel execution — all aimed at improving clinical decision-making and measurable marketing impact.
